Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?
Value in Health · 2024
DOI: 10.1016/j.jval.2023.12.005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Value in Health, 2024. Verfasst von Rhys Williamson und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: University of Queensland, State Government of Victoria, National Health and Medical Research Council.
Abstract (Originalsprache)
OBJECTIVES: Biosimilar market launch delays are likely costing healthcare systems billions of dollars and preventing patients accessing affordable biologic therapies sooner. Many claim these delays are mostly caused by originator biologics' large patent portfolios asserted during litigation against biosimilar developers, particularly that the manufacturing patents filed after the originator is approved is an important driver of these delays. Our objective was to investigate the accuracy of these claims. METHODS: We reviewed US Court document submissions for litigation data, including the details of patents asserted against biosimilar owners, and collated biosimilar market launch dates from publicly available databases. RESULTS: We find that, although approximately half of all patents asserted in litigation were manufacturing patents, a greater proportion of composition, active pharmaceutical ingredient, and treatment patents are associated with longer market launch delays, whereas a greater proportion of manufacturing patents are associated with shorter market launch delays. CONCLUSIONS: Our results suggest that manufacturing patents were having less of an impact on market launch delays than other types of patents. Our findings have implications for both biosimilar and originator developers, as well as patent policy and its association with healthcare accessibility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia.
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, St Lucia, Queensland, Australia.
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia; Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, Australia.
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia; Institute for Molecular Bioscience, The University of Queensland, St Lucia, Queensland, Australia.
- School of Chemistry and Molecular Biosciences, The University of Queensland, St Lucia, Queensland, Australia. Electronic address: lisette.pregelj@uq.edu.au.
Förderung
- University of Queensland
- State Government of Victoria
- National Health and Medical Research Council
Zitieren
APA
Williamson, R., Munro, T., Ascher, D., Robertson, A., & Pregelj, L. (2024). Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?. Value in Health. https://doi.org/10.1016/j.jval.2023.12.005
Vancouver
Williamson R, Munro T, Ascher D, Robertson A, Pregelj L. Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?. Value in Health. 2024. doi:10.1016/j.jval.2023.12.005
BibTeX
@article{Williamson2024,
author = {Williamson, Rhys and Munro, Trent and Ascher, David and Robertson, Avril and Pregelj, Lisette},
title = {Are Manufacturing Patents to Blame for Biosimilar Market Launch Delays?},
journal = {Value in Health},
year = {2024},
doi = {10.1016/j.jval.2023.12.005}
}
EUVIMED